Control of Established Colon Cancer Xenografts Using a Novel Humanized Single Chain Antibody-Streptococcal Superantigen Fusion Protein Targeting the 5T4 Oncofetal Antigen-Reference-Cited by-同舟云学术

Control of Established Colon Cancer Xenografts Using a Novel Humanized Single Chain Antibody-Streptococcal Superantigen Fusion Protein Targeting the 5T4 Oncofetal Antigen

Published:2014-04-15 Issue:4 Volume:9 Page:e95200
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Patterson Kelcey G.,Dixon Pittaro Jennifer L.,Bastedo Peter S.,Hess David A.,Haeryfar S. M. Mansour,McCormick John K.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference74 articles.

1. Toxic shock syndrome and bacterial superantigens: an update;JK McCormick;Annu Rev Microbiol,2001

2. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen;TS Jardetzky;Nature,1994

3. Toxic shock syndrome toxin-1 complexed with a class II major histocompatibility molecule HLA-DR1;J Kim;Science,1994

4. Crystal structure of a superantigen bound to the high-affinity, zinc-dependent site on MHC class II;Y Li;Immunity,2001

5. Crystal structure of a superantigen bound to MHC class II displays zinc and peptide dependence;K Petersson;EMBO J,2001

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insights into the enigma of oral streptococci in carcinogenesis;Microbiology and Molecular Biology Reviews;2024-06-27

2. Group A streptococcal collagen-like protein 1 restricts tumor growth in murine pancreatic adenocarcinoma and inhibits cancer-promoting neutrophil extracellular traps;Frontiers in Immunology;2024-03-07

3. Group A Streptococcal Collagen-like Protein 1 Restricts Tumor Growth in Murine Pancreatic Adenocarcinoma and Inhibits Cancer-Promoting Neutrophil Extracellular Traps;2024-01-20

4. Antibody fragment and targeted colorectal cancer therapy: A global systematic review;Current Pharmaceutical Biotechnology;2021-08-10

5. Superantigens, superantigen-like proteins and superantigen derivatives for cancer treatment;EUR REV MED PHARMACO;2021